Mometasone Furoate Nasal Spray for Allergies and Sinuses

Mometasone furoate nasal spray is a corticosteroid delivered directly into the nose to reduce inflammation, and it ranks among the most widely used treatments for allergic rhinitis, nasal polyps, and certain sinus conditions. Originally available only by prescription (under the brand name Nasonex), it has since become available over the counter in many countries, making it one of the first-line options people reach for during allergy season. What makes mometasone stand out is the combination of strong local anti-inflammatory action with remarkably little absorption into the rest of the body, a profile that shapes nearly every practical question about the drug.

How It Works Inside the Nose

Mometasone furoate binds tightly to glucocorticoid receptors on cells lining the nasal passages. Once bound, it dials down the production of inflammatory chemicals that cause swelling, mucus overproduction, and itching. The furoate portion of the molecule is not just a naming convention; it contributes to the drug’s grip on the receptor. Structural studies show that the furoate group fits into a specific pocket on the glucocorticoid receptor, creating favorable contact that helps explain the drug’s high binding strength.¹ In receptor-binding assays, mometasone furoate scores a relative affinity of about 2,200 when dexamethasone is set at 100, putting it higher than many competing corticosteroids.²

That high affinity translates into potent suppression of the inflammatory cascade in nasal tissue, though it is worth noting that receptor affinity alone does not determine clinical effectiveness. Lab comparisons have shown that fluticasone furoate (a newer corticosteroid used in some competing sprays) can outperform mometasone furoate in suppressing certain inflammatory markers in nasal tissue samples, consistent with fluticasone furoate’s even higher receptor affinity.³ In real-world use, though, the clinical differences between these sprays tend to be small, as discussed further below.

How Quickly It Starts Working

One of the most common frustrations with nasal steroid sprays is waiting for them to kick in. Mometasone furoate is faster than many people expect, though it is not instant. In a clinical trial of seasonal allergy sufferers, roughly a quarter of patients experienced meaningful relief within 12 hours of the first dose, compared with about one in eight on placebo. The median time to at least moderate symptom improvement was about 36 hours.⁴ An older review placed the onset of action at roughly seven hours for measurable effects on nasal symptoms.⁵

The practical takeaway is that you may notice some difference on day one, but the full benefit builds over several days of consistent use. Many people abandon nasal steroid sprays after a couple of doses because they expect the rapid punch of a decongestant. That is a mistake. The drug works by gradually calming inflammation, not by mechanically opening the airways. If you are heading into allergy season, starting the spray a day or two before peak pollen exposure gives it time to build up its protective effect.

Allergic Rhinitis

This is the bread-and-butter use for mometasone furoate nasal spray. A meta-analysis pooling data from randomized, double-blind, placebo-controlled trials including about 3,000 patients found that the spray produced a significant reduction in total nasal symptom scores compared to placebo.⁶ That encompasses the full package of allergy symptoms: sneezing, congestion, runny nose, and nasal itching.

Mometasone works for both seasonal allergies (tree, grass, and weed pollens) and year-round allergies (dust mites, pet dander, mold). The standard adult dose for allergic rhinitis is two sprays in each nostril once daily. For many people, once symptoms are controlled, the dose can be reduced to one spray per nostril.

Nasal Polyps

Nasal polyps are soft, noncancerous growths that develop in the lining of the nasal passages or sinuses, often in people with chronic inflammation. Mometasone furoate nasal spray is one of the few medications with good trial evidence for shrinking these polyps and relieving the congestion and smell loss they cause. In a four-month randomized trial, patients using the spray twice daily saw a statistically significant reduction in polyp size and meaningful improvement in nasal congestion compared to placebo. The once-daily dose also improved congestion, though the twice-daily regimen was more effective at shrinking the polyps themselves.⁷

A separate trial focused on patients with mild-to-moderate polyps confirmed that once-daily use significantly decreased congestion, reduced polyp size, and improved quality of life, including sense of smell and nasal airflow.⁸ Research in Chinese patients replicated these findings, showing significant reductions in both congestion scores and total polyp size with the spray versus placebo over 16 weeks.⁹ The consistency across different populations is reassuring. For people with recurring polyps after surgery, long-term maintenance with a corticosteroid spray like mometasone is standard practice to slow regrowth.

Sinus Infections

Mometasone furoate nasal spray has also been studied for acute rhinosinusitis, the condition most people call a sinus infection. Clinical trials have found it effective both as a supplement to antibiotics and as a standalone treatment for uncomplicated cases that are likely viral. In one trial, twice-daily use produced greater symptom improvement than amoxicillin or placebo for adults with acute uncomplicated sinusitis.¹⁰ This matters because the majority of sinus infections are viral and do not benefit from antibiotics. A steroid spray that reduces swelling and drainage obstruction without contributing to antibiotic resistance has obvious appeal.

Why So Little Enters the Bloodstream

A recurring concern with any steroid medication is whether it causes body-wide side effects. Mometasone furoate nasal spray has one of the lowest systemic bioavailabilities of any intranasal corticosteroid, measured at under half a percent of the administered dose.¹¹ Two factors drive this. First, mometasone furoate dissolves poorly in water, which limits how much can cross the nasal lining into the blood. Second, any drug that is swallowed (and a large portion of nasal spray inevitably is) gets broken down almost completely by the liver before it can circulate.¹² No bioactive metabolites have been found in humans after nasal use, which essentially means what reaches the bloodstream does nothing steroid-like elsewhere in the body.

This pharmacokinetic profile is what makes long-term daily use feasible for conditions like chronic allergic rhinitis and nasal polyps, where treatment stretches over months or years.

Common Side Effects

The most frequent complaint is nosebleeds. A systematic review and meta-analysis covering intranasal corticosteroid sprays as a class found that these drugs roughly doubled the risk of epistaxis compared to placebo, with mometasone furoate among the agents associated with elevated risk.¹³ In practice, these nosebleeds are usually minor streaks of blood in mucus rather than full-blown bleeds. Proper spray technique, which involves aiming the nozzle away from the nasal septum (the center wall of the nose) and toward the outer wall of each nostril, significantly reduces irritation to the delicate blood vessels on the septum.

Other reported side effects include headache, throat irritation, and occasionally a mild stinging sensation in the nose. Nasal septal perforation (a hole in the septum) has been reported with prolonged use of any nasal steroid spray, though it is rare. If you notice persistent crusting or whistling when you breathe through your nose, that warrants a check-in with your doctor.

Safety in Children

Growth suppression is the concern that keeps parents up at night when their child is prescribed a steroid, even a topical one. A year-long placebo-controlled trial in children with year-round allergic rhinitis directly addressed this. Children treated with mometasone furoate nasal spray showed no growth suppression over 12 months. The average rate of growth was identical between the spray and placebo groups, and the drug did not slow growth in any sex or age subgroup.¹⁴ The children on the spray actually had a slightly greater increase in height at the one-year mark (about 7 cm versus 6.4 cm), though that difference was not large enough to be meaningful in itself.

This growth safety profile is not universal among intranasal steroids. Some other corticosteroid sprays have shown small but measurable growth effects in similar studies. Mometasone’s negligible systemic absorption likely explains why it performs well on this front. The spray is approved for children as young as two years old for allergic rhinitis (at a lower dose of one spray per nostril).

Use During Pregnancy

Allergic rhinitis often worsens during pregnancy due to hormonal changes, and untreated nasal congestion can disrupt sleep and quality of life. A review of the safety data for intranasal corticosteroid sprays during pregnancy concluded that mometasone, along with budesonide and fluticasone furoate, appears safe when used at recommended doses after proper medical evaluation.¹⁵ The evidence base is not as robust as clinicians would like, since pregnant women are typically excluded from clinical trials, but the available data have not raised red flags. Many allergy guidelines list budesonide as the preferred intranasal steroid in pregnancy because it has the longest track record, but mometasone is considered an acceptable alternative.

How It Compares to Other Nasal Steroid Sprays

Head-to-head trials between mometasone furoate and fluticasone propionate (the other dominant nasal steroid spray) consistently show they are clinically equivalent. In a study of perennial rhinitis, mometasone was significantly better than placebo and statistically indistinguishable from fluticasone propionate at the same dose, with both producing roughly a 37 to 39 percent reduction in nasal symptoms from baseline.¹⁶ A pediatric trial in children with dust-mite allergies found mometasone was slightly better for nasal symptoms specifically, while fluticasone propionate showed an edge for non-nasal symptoms like eye or throat irritation, though both reduced overall symptom burden significantly.¹⁷

For chronic rhinosinusitis, a hospital-based study comparing mometasone furoate and fluticasone furoate sprays over a year found both produced significant symptom improvement, with no meaningful difference between the two.¹⁸ The honest summary is that for most people, the choice between mometasone and fluticasone comes down to cost, insurance coverage, and personal preference for one spray’s feel or scent over another. The efficacy gap, if one exists, is too small to detect reliably in clinical trials.

Eye Symptom Relief From a Nose Spray

This is one of the more surprising findings about mometasone furoate nasal spray: it helps with allergy-related eye symptoms like itching, tearing, and redness, even though you are spraying it in your nose, not your eyes. A pooled analysis of clinical trials involving over 3,100 patients showed significant reductions in all three individual eye symptoms in people with seasonal and year-round allergies treated with the spray.¹⁹ A separate trial confirmed that the spray reduced total ocular symptom scores significantly more than placebo, including eye itching, burning, and watering.²⁰

The likely explanation is the nasolacrimal reflex. The nose and eyes share drainage pathways, and reducing nasal inflammation appears to dampen the allergic response in the eyes as well. For people whose seasonal allergies hit both nose and eyes, this means a nasal steroid spray may reduce the need for separate eye drops.

Combination Sprays With Antihistamines

A newer development is combining mometasone furoate with olopatadine, an antihistamine, in a single nasal spray. The logic is that the antihistamine provides fast-acting symptom relief while the steroid addresses the underlying inflammation. Clinical trials have shown this combination spray produces significantly greater improvements in nasal symptom scores than either ingredient used alone.²¹ An environmental exposure chamber study (where subjects are exposed to controlled levels of allergen) confirmed that the combination provided significant symptom improvement over placebo with both once-daily and twice-daily dosing.²²

A similar concept already exists with azelastine plus fluticasone propionate (sold as Dymista), which has been on the market longer. The olopatadine-mometasone combination represents competition in this space. For people who find that a steroid spray alone does not fully control their symptoms, these combination products offer meaningful added benefit without the hassle of carrying two separate bottles.

Where the Spray Actually Goes in Your Nose

Spray technique matters more than most people realize. A deposition study using radiolabeled mometasone furoate found that the spray delivered about 86 percent of the metered dose into the nasal cavity, with roughly 60 percent reaching the posterior (back) portion of the nose. However, mucociliary clearance, the nose’s built-in self-cleaning system, removed about 59 percent of the deposited drug within 15 minutes.²³ That rapid clearance is a reminder that the drug works through repeated daily dosing, not single heroic applications.

Some practical tips for getting the most out of each dose: gently blow your nose before spraying to clear excess mucus, prime the pump if you have not used it in a while, aim the nozzle slightly outward (toward the ear on the same side), and avoid sniffing hard after spraying. A gentle breath in through the nose is all that is needed. Tilting the head forward slightly can help the spray reach the middle meatus, the drainage pathway for most of the sinuses.

COVID-19 and Smell Loss

When millions of people lost their sense of smell during the COVID-19 pandemic, mometasone furoate nasal spray was one of the treatments clinicians tried. The results have been mixed. One randomized trial found that adding the spray to olfactory training (a structured smell-retraining protocol) did not offer any advantage over olfactory training alone for overall recovery rates or duration of smell loss.²⁴ A second randomized, double-blind trial painted a more nuanced picture: while overall smell test scores did not differ significantly between the groups, the combination of mometasone plus olfactory training showed greater improvement specifically in patients with severe chronic smell loss from COVID-19.²⁵

The takeaway is that mometasone furoate nasal spray is not a reliable cure for post-COVID smell loss in the general case, but it may help a subset of patients with more severe or persistent anosmia when combined with structured olfactory training. Olfactory training itself, which involves deliberately sniffing a set of distinct scents for several minutes each day, remains the best-supported intervention for this problem.

Effects on the Nasal Microbiome

An emerging area of research asks what long-term nasal steroid spray use does to the community of bacteria living in the nose. A pilot study using genetic sequencing found that intranasal steroid use shifted the composition and diversity of the nasal microbiome. Treatment appeared to increase the relative abundance of staphylococci while suppressing other groups like Moraxella and streptococci, and some of these shifts persisted even after the spray was stopped.²⁶ A separate study looking specifically at mometasone found no statistically significant change in overall bacterial counts after a month of use, but did observe that some individual patients acquired new potentially pathogenic bacteria in their nasopharynx, including Staphylococcus aureus and Pseudomonas aeruginosa.²⁷

The clinical significance of these microbiome shifts is still unclear. The studies are small, and no one has yet demonstrated that steroid-induced changes in nasal bacteria lead to infections or other problems in otherwise healthy users. But the research is a reminder that the nose is not a sterile environment, and anything applied to it regularly will interact with the ecosystem already there. For people on long-term therapy, periodic check-ins with a physician to assess the nasal lining remain good practice.

The Preservative Question

Many mometasone furoate nasal spray formulations contain benzalkonium chloride as a preservative, which has been a source of debate for years. Some laboratory studies have shown benzalkonium chloride can slow the beating of nasal cilia (the tiny hair-like structures that sweep mucus and debris through the nose), while other studies have found no harmful effect on the nasal lining.²⁸ When researchers tested a mometasone furoate spray formulation on a lab model of human nasal tissue, they observed a short-term stimulatory effect on ciliary beating and no structural damage to the tissue afterward.²⁹

Preservative-free formulations do exist for some nasal steroid sprays, and if you are someone with unusually sensitive nasal passages or plan to use the spray for years, asking your pharmacist about preservative-free options is reasonable. For most users, though, the concentrations of benzalkonium chloride in approved nasal sprays have not been shown to cause meaningful harm in real-world use.